[This Week's IPO] Book-Building and Subscription Schedule for the Second Week of March View original image

During the second week of this month (March), Cosmo Robotics, Resense Medical, and Inventera will conduct book-building for institutional investors. IM Biologics is preparing for its public offering for retail investors.


<Book-building>


◆Cosmo Robotics = Established in 2016, Cosmo Robotics is a global leader specializing in medical and rehabilitation wearable robot technologies. The company is expanding its presence in the domestic and international rehabilitation medical market with products such as the Bambini Kids rehabilitation robot for infants and young children, the Bambini Teens for adolescents, the EA2 PRO for adults, the COSuit walking assist robot, and the EA Personal customized walking assist device.


The total number of shares to be offered is 4.17 million, and the desired price band is between KRW 5,300 and KRW 6,000. The expected total amount to be raised is approximately KRW 22.1 billion to KRW 25 billion. The book-building for institutional investors, which will determine the final offering price, will be held over five days from March 9 to March 13. The subscription for retail investors will take place over two days from March 18 to March 19. The lead underwriters are Eugene Investment & Securities and NH Investment & Securities.


◆Resense Medical = Founded in 2016, Resense Medical is a medical device company that has developed its own proprietary precision cooling technology to address unmet needs in clinical settings. By rapidly controlling the temperature of cryogenic refrigerants, the company provides cooling solutions for areas such as dermatology, ophthalmology, and veterinary medicine, quickly lowering the target area to the desired temperature.


The company plans to offer a total of 1.4 million shares, with a desired price band of KRW 9,000 to KRW 11,000. Book-building will be conducted over five business days from March 9 to March 13, and the subscription for retail investors will take place over two days from March 19 to March 20. The lead underwriters are KB Securities and Korea Investment & Securities.


◆Inventera = Inventera's core technology, Invinity™, is a polysaccharide-based nano drug delivery platform. The technology addresses issues such as immune cell phagocytosis and particle aggregation that have occurred with conventional nano drugs, enabling more effective delivery of drugs to lesion sites. The platform's applicability and safety for human use have been verified through pipelines currently in Phase 3 clinical trials.


The company plans to offer a total of 1.18 million shares. The desired offering price is between KRW 12,100 and KRW 16,600, and the expected amount to be raised is approximately KRW 14.3 billion to KRW 19.6 billion. The company aims to complete both book-building and retail subscription within March 2026 and to be listed on the KOSDAQ market in the first half of 2026. The lead underwriter is NH Investment & Securities, with Eugene Investment & Securities as the co-lead underwriter.


<Public Subscription>


◆IM Biologics = The desired offering price is between KRW 19,000 and KRW 26,000. Book-building was conducted until March 6, and the subscription for retail investors will be held from March 11 to March 12. The underwriters are Korea Investment & Securities and Shinhan Investment & Securities.



Founded in 2020, IM Biologics is a biopharmaceutical company focused on developing antibody drugs targeting autoimmune diseases. Recognized for the value of its pipeline based on its unique platform technology, it passed the technology evaluation threshold last July, receiving A and A grades from two professional evaluation agencies.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing